New York is currently home to 4447 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
NICU Antibiotics and Outcomes Trial
Recruiting
The goal of the NANO trial is to study the longstanding clinical practice of empirically administering intravenous antibiotics to extremely low birthweight (ELBW) infants in the first days of life. In this 802-subject multicenter placebo-controlled randomized clinical trial, the hypothesis to be tested is that the incidence of adverse outcomes is higher in babies receiving empiric antibiotics (EA) in the first week of life compared to babies receiving placebo. The study targets a population of E... Read More
Gender:
ALL
Ages:
4 hours and below
Trial Updated:
01/02/2025
Locations: SUNY Downstate Medical Center, Brooklyn, New York
Conditions: Microbial Colonization, Extreme Prematurity, Early-Onset Neonatal Sepsis, Late-Onset Neonatal Sepsis, Necrotizing Enterocolitis of Newborn, Death; Neonatal
Screening for AL Amyloidosis in Smoldering Multiple Myeloma
Recruiting
In this multicenter study, we will recruit 400 patients 40 years of age or older at 15 centers with a diagnosis of smoldering multiple myeloma (SMM), a group of patients for whom standard of care is observation not treatment. The main goal of this study is to screen for the diagnosis of light-chain amyloidosis (AL) before the onset of symptomatic disease and to develop a training set for a likelihood algorithm.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
12/31/2024
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Smoldering Multiple Myeloma
Collaborative Care for Polysubstance Use in Primary Care Settings (Co-Care)
Recruiting
The purpose of this trial is to test the efficacy of a collaborative care intervention to address opioid- and/or stimulant-involved polysubstance use in adult primary care patients with moderate to severe substance use disorders (SUD). The primary aims are to reduce days of opioid use (illicit or nonmedical opioid use), days of illicit stimulant use (cocaine, methamphetamine), and days of heavy alcohol use.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/30/2024
Locations: NYU Langone Health, New York, New York
Conditions: Substance Use
Evaluating a Noise Reduction Algorithm With Cochlear Implant Users
Recruiting
In this study, a noise reduction algorithm will be implemented in various listening situations to evaluate its effectiveness in improving speech understanding for cochlear implant users ages 12 and older.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
12/30/2024
Locations: Tisch Hospital, New York, New York
Conditions: Hearing Impairment
Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
Recruiting
The main purpose of this study is to see how pancrelipase affects the body mass index (BMI) in people with metastatic PDAC. BMI is a measure based on a person's height and weight. Other study goals are to explore two different dosing schedules of pancrelipase and to evaluate pancrelipase in people who do not have symptoms of EPI.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/30/2024
Locations: Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities), Commack, New York
Conditions: Metastatic Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma, Metastatic Pancreatic Carcinoma, Pancreatic Carcinoma, Pancreatic Carcinoma Metastatic, Pancreatic Carcinoma Non-resectable, Pancreatic Cancer, Pancreatic Cancer Non-resectable, Pancreatic Cancer Stage IV, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer
Recruiting
The purpose of this study is to see whether 68Gallium PSMA-PET/CT scans are an effective way to detect sites of cancer in people with metastatic bladder cancer or skin cancer. The study researchers want to learn if a 68Gallium PSMA PET/CT scan will work better, the same, or not as well as the PET/CT scans doctors usually use for imaging bladder cancer or skin cancer (FDG-PET/CT scan).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/30/2024
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Bladder Cancer
Screening Women With Prior HPV for Anal Neoplasia
Recruiting
The goal of this single arm trial is to prospectively evaluate screening methods for anal cancer precursors in HIV uninfected women with a history of lower genital tract neoplasias and cancers.
Gender:
FEMALE
Ages:
35 years and above
Trial Updated:
12/30/2024
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: HPV-related Lower Genital Tract Neoplasias, HPV-related Anal Neoplasias, Early Stage Lower Genital Tract Cancers
Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant
Recruiting
This phase II trial studies how well ustekinumab works in preventing acute graft-versus-host disease after unrelated donor hematopoietic cell transplant. Sometimes the transplanted cells from a donor can attack the body's normal tissues (called graft-versus-host disease). Giving ustekinumab after the transplant may help prevent acute graft-versus-host disease by controlling the body's immune response. Funding Source- FDA OOPD.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
12/30/2024
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Hematologic and Lymphocytic Disorder, Hematopoietic and Lymphoid System Neoplasm
A Study of Enasidenib in People With T-Cell Lymphoma
Recruiting
The researchers are doing this study to find out whether enasidenib is a safe treatment for people with angioimmunoblastic T-cell lymphoma (AITL) that has an IDH2 mutation. The researchers will look at the safety of enasidenib when it is given alone or in combination with the drug rituximab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/27/2024
Locations: Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity), Commack, New York
Conditions: T-cell Lymphoma
A Study of Pasireotide in People With Prolactinoma
Recruiting
The researchers are doing this study to find out whether pasireotide is an effective treatment for people with prolactinoma who cannot receive dopamine agonist therapy. Another purpose of this study is to find out whether pasireotide is a safe treatment for people with prolactinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/27/2024
Locations: Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities), Commack, New York
Conditions: Prolactin-Producing Pituitary Tumor
Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC
Recruiting
Open-label, Phase II, randomized, controlled study evaluating the efficacy and safety of danvatirsen in combination with pembrolizumab compared with pembrolizumab alone as first-line treatment of patients with recurrent/metastatic (R/M) HNSCC. Two-thirds of patients will be randomized to receive danvatirsen and pembrolizumab and one-third will be randomized to receive pembrolizumab alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/27/2024
Locations: Mount Sinai, New York, New York
Conditions: HNSCC
A Study of ZEN003694 in People With Squamous Cell Lung Cancer
Recruiting
The purpose of this study is to find out whether ZEN003694 is an effective treatment for people with advanced squamous cell lung cancer with a mutation in the NSD3 gene. ZEN003694 is a type of drug called a BET inhibitor. Researchers think ZEN003694 may help here because the drug works by blocking a group of proteins called bromodomain and extra-terminal (BET) proteins, which may counteract the effect of NSD3 on tumor growth. Blocking these proteins may slow or stop the growth of the cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/27/2024
Locations: Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities ), Commack, New York
Conditions: Squamous Cell Lung Cancer